Archives: Research
Research & Insights Content Type
-
Xeljanz, the FDA, and nine years of patient harm
-
Atypical antipsychotics: Decades of use, unfathomable harms
-
Medicare Part B Premium Dynamics Explained
-
Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
-
Evaluating Industry’s Drug Pricing Claims
-
Mapping conflict of interests: scoping review
-
Production Plus Profit Pricing (P-quad) FAQ
-
What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs
-
Medicare Must Study Unproven, Expensive Alzheimer’s Drug